Молекулярные детерминанты тройного негативного рака молочной железы

##plugins.themes.bootstrap3.article.sidebar##

pdf
Опубликован: апр 3, 2026
DOI: https://doi.org/10.17072/1994-9952-2026-1-82-101
Ключевые слова:
трижды негативный рак молочной железы молекулярные детерминанты TP53, PTEN, BRCA1, PIK3CA, EGFR иммунное микроокружение PD1, PD-L1, CTLA4 цитокины

##plugins.themes.bootstrap3.article.main##

Владислав Юрьевич Буслаев
Федеральный исследовательский центр угля и углехимии СО РАН, Кемерово, Россия
Наталья Сергеевна Маниковская
Кемеровский государственный университет, Кемерово, Россия
Варвара Ивановна Минина
Кемеровский государственный университет, Кемерово, Россия

Аннотация

Рак молочной железы занимает второе место по распространенности среди онкологических заболеваний. В последнее время отмечается рост случаев заболеваемости и смертности раком молочной железы среди населения России. Наиболее агрессивной формой рака молочной железы является тройной негативный (трижды негативный) тип. Выполняемые исследования сфокусированы на попытках объяснить генетические и иммунологические механизмы его возникновения, прогрессии и устойчивости к терапии. Нами был выполнен систематический анализ современных данных литературы, касающихся различных факторов развития трижды негативного рака молочной железы. Поиск научных публикаций был выполнен в следующих базах данных: PubMed, Scopus, Web of Science, Embase, Cochrane CENTRAL, Google Scholar, e-library. Поиск источников осуществлялся с использованием ключевых слов: рак молочной железы, тройной негативный тип, онкогены, наследственные формы, иммунологические факторы, генетические факторы, генетический полиморфизм. Производился поиск статей на английском и русском языках. В результате в обзор было включено 83 статьи, опубликованных за последние 10 лет, включающих обсуждение различных аспектов генетической предрасположенности к формированию тройного негативного типа рака молочной железы. Сведения о генетической составляющей расширяют возможности для проведения будущих фундаментальных исследований.

##plugins.themes.bootstrap3.article.details##

Как цитировать
Буслаев, В. Ю., Маниковская, Н. С., & Минина, В. И. (2026). Молекулярные детерминанты тройного негативного рака молочной железы. Вестник Пермского университета. Серия Биология, 17(1), 82–101. https://doi.org/10.17072/1994-9952-2026-1-82-101
Выпуск
Том 17 № 1 (2026): Вестник Пермского университета. Серия Биология
Раздел
Иммунология

Лицензионный договор на право использования научного произведения в научных журналах, учредителем которых является Пермский государственный национальный исследовательский университет

Скачать лицензионный договор

Текст Договора размещен на сайте Пермского государственного национального исследовательского университета http://www.psu.ru/, а также его можно получить по электронной почте в «Отделе научных периодических и продолжающихся изданий ПГНИУ»: YakshnaN@psu.ru или в редакциях научных журналов ПГНИУ.

Биографии авторов

Владислав Юрьевич Буслаев, Федеральный исследовательский центр угля и углехимии СО РАН, Кемерово, Россия

Ведущий инженер-технолог лаборатории цитогенетики

Наталья Сергеевна Маниковская, Кемеровский государственный университет, Кемерово, Россия

Канд. биол. наук, доцент кафедры генетики и фундаментальной медицины

Варвара Ивановна Минина, Кемеровский государственный университет, Кемерово, Россия

Д-р биол. наук, доцент, заведующий кафедрой генетики и фундаментальной медицины
Crossref
Scopus
Google Scholar
Europe PMC

Библиографические ссылки

Glushkov A.N., Polenok E.G., Gordeeva L.A., Mun S.A., Kostyanko M.V., Antonov A.V. et al. [Immuno-logical imbalance in breast cancer and lung cancer in postmenopausal women]. Medicinskaja immunologija. V. 20, No. 6 (2018): pp. 927-934. (In Russ.). DOI: 10.15789/1563-0625-2018-6-927-934. EDN: YOOZQT.

Glushkov A.N., Polenok E.G., Mun S.A., Gordeeva L.A., Kostyanko M.V., Antonov A.V. et al. [Synergistic action of steroid hormones and hormone-specific autoantibodies in breast cancer progression]. Fundamen-tal’naja i kliničeskaja medicina. V. 8 (2023): pp. 19-32. (In Russ.). DOI: 10.23946/2500-0764-2023-8-2-19-32. EDN: EIEPMV.

Zavarykina T.M., Lomskova P.K., Kapralova M.A., Gordeeva O.O., Ganshina I.P., Khodyrev D.S. et al. [Association of polymorphic markers of the XRCC1, ERCC5, TP53, CDKN1A1 genes with the survival of pa-tients after platinum-based chemotherapy for triple negative breast cancer]. Opucholi ženskoj reproductivnoj systemy. V. 18 (2022): pp. 69-80. (In Russ.). DOI: 10.17650/1994-4098-2022-18-4-69-80. EDN: WZLBAD.

Timofeeva A.A., Minina V.I., Torgunakova A.V., Soboleva O.A., Titov R.A., Savchenko Ya.A. et al. [Breast cancer of luminal A subtype in women and genes of the antioxidant defense system]. Vestnik novych medicinskich technologij. V. 30 (2023): pp. 92-95. (In Russ.). DOI: 10.24412/1609-2163-2023-4-92-95. EDN: RVNUNY.

Titov R.A., Glushkov A.N., Torgunakova A.V., Zakharova Y.A., Maruschak A.V., Minina V.I. [Study of polymorphism of DNA repair genes in the formation of predisposition to the development of triple negative breast cancer in women]. Bulletin of the Perm University. Biology. Iss. 4 (2024): рр. 440-450. (In Russ.). DOI: 10.17072/1994-9952-2024-4-440-450. EDN: THLYAU.

Torgunakova A.V., Minina V.I., Glushkov A.N., Soboleva O.A., Astafieva E.A., Yakovleva A.A. et al. [Studying the role of DNA repair gene polymorphism and the cell cycle in formation of predisposition to the de-velopment of breast cancer]. Vestnik novych medicinskich technologij. V. 29 (2022): pp. 83-90. (In Russ.). DOI: 10.24412/1609-2163-2022-3-83-90. EDN: NEZJKD.

Abdulkarim S., Quarshie J.T., Birokorang P.A., Mawuli M.A., Baffoe S.M., Abrahams A. et al. Role of the IL-8/CXCR2 axis in promoting vasculogenic mimicry in triple-negative breast cancer through epithelial-mesenchymal transition. Cancer Plus. V. 8 (2024). Art. 3356. DOI: 10.36922/cp.3356. EDN: GYGUUV.

Andreopoulou E., Schweber S.J., Sparano J.A., McDaid H.M. Therapies for triple negative breast cancer. Expert Opin Pharmacother. V. 16 (2015): pp. 983-998. DOI: 10.1517/14656566.2015.1032246. EDN: UOPYNX.

Arnold M., Morgan E., Rumgay H., Mafra A., Singh D., Laversanne M. et al. Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast. V. 66 (2022): pp. 15-23. DOI: 10.1016/j.breast.2022.08.010. EDN: TFCNLV.

Aziz A., Salleh S., Yahya M.M., Zakaria A.D., Ankathil R. Genetic Association of CYP1B1 4326 C>G Polymorphism with Disease-Free Survival in TNBC Patients Undergoing TAC Chemotherapy Regimen. Asian Pac. J. Cancer Prev. V. 22 (2021): pp. 1319–1324. DOI: 10.31557/APJCP.2021.22.4.1319.

Badve S.S., Penault-Llorca F., Reis-Filho J.S., Deurloo R., Siziopikou K.P., D'Arrigo C. et al. Determining PD-L1 Status in Patients With Triple-Negative Breast Cancer: Lessons Learned From IMpassion130. J. Natl. Cancer Inst. V. 114 (2022): pp. 664-675. DOI: 10.1093/jnci/djab121.

Baranova A., Krasnoselskyi M., Starikov V., Kartashov S., Zhulkevych I., Vlasenko V. et al. Triple-negative breast cancer: current treatment strategies and factors of negative prognosis. J. Med. Life. V. 15 (2022): pp. 153-161. DOI: 10.25122/jml-2021-0108. EDN: RVJIBT.

Boguszewska-Byczkiewicz K., Wow T., Szymańska B., Kosny M., Kolacinska-Wow A. The PD-1 single-nucleotide polymorphism rs11568821 and rs2227981 as a novel prognosis model in a triple-negative breast cancer patient. Mol. Biol. Rep. V. 50 (2023): pp. 6279-6285. DOI: 10.1007/s11033-023-08423-3.

Chai C., Wu H.H., Abuetabh Y., Sergi C., Leng R. Regulation of the tumor suppressor PTEN in triple-negative breast cancer. Cancer Lett. V. 527 (2022): pp. 41-48. DOI: 10.1016/j.canlet.2021.12.003.

Chakravarty L., Ahmad S.I., Khatun A., Khan S.A. Exploring the potential of CRISPR in triple-negative breast cancer treatment. Innovative Practice in Breast Cancer. V. 7 (2025). Art. 100028. DOI: 10.1016/j.ibreh.2024.100028.

Chen H., Wu J., Zhang Z., Tang Y., Li X., Liu S. et al. Association Between BRCA Status and Triple-Negative Breast Cancer: A Meta-Analysis. Front Pharmacol. V. 9 (2018). Art. 909. DOI: 10.3389/fphar.2018.00909.

Chen H., Ding Q., Khazai L., Zhao L., Damodaran S., Litton J.K. et al. PTEN in triple-negative breast car-cinoma: protein expression and genomic alteration in pretreatment and posttreatment specimens. Ther. Adv. Med. Oncol. V. 15 (2023): Art. 17588359231189422. DOI: 10.1177/17588359231189422.

Chen J.W., Murugesan K., Newberg J.Y., Sokol E.S., Savage H.M., Stout T.J. et al. Comparison of PIK3CA Mutation Prevalence in Breast Cancer Across Predicted Ancestry Populations. JCO Precis. Oncol. V. 6 (2022). Art. e2200341. doi: 10.1200/PO.22.00341. EDN: GTHOKQ.

Conte B., Brasó-Maristany F., Rodríguez Hernández A., Pascual T., Villacampa G., Schettini F. et al. A 14-gene B-cell immune signature in early-stage triple-negative breast cancer (TNBC): a pooled analysis of seven studies. EBioMedicine. V. 102 (2024). Art. 105043. DOI: 10.1016/j.ebiom.2024.105043.

Deng F., Weng Y., Li X., Wang T., Fan M., Shi Q. Overexpression of IL-8 promotes cell migration via PI3K-Akt signaling pathway and EMT in triple-negative breast cancer. Pathol. Res. Pract. V. 216 (2020). Art. 152902. DOI: 10.1016/j.prp.2020.152902.

Derkyi-Kwarteng L., Ghartey F.N., Aidoo E., Addae E., Imbeah E.G., Brown A.A. et al. A retrospective analysis suggests PTEN expression is associated with favorable clinicopathological features of breast cancer. Sci. Rep. V. 14 (2024). Art. 21645. DOI: 10.1038/s41598-024-69252-3.

Domagala P., Hybiak J., Cybulski C., Lubinski J. BRCA1/2-negative hereditary triple-negative breast cancers exhibit BRCAness. Int. J. Cancer. V. 140 (2017): pp. 1545-1550. DOI: 10.1002/ijc.30570.

Dominguez C., McCampbell K.K., David J.M., Palena C. Neutralization of IL-8 decreases tumor PMN-MDSCs and reduces mesenchymalization of claudin-low triple-negative breast cancer. JCI Insight. V. 21 (2017). Art. e94296. DOI: 10.1172/jci.insight.94296.

Du X.L., Li Z. Incidence trends in triple-negative breast cancer among women in the United States from 2010 to 2019 by race/ethnicity, age and tumor stage. Am. J. Cancer Res. V. 13 (2022): pp. 678-691.

Ertay A., Liu H., Liu D., Peng P., Hill C., Xiong H. et al. WDHD1 is essential for the survival of PTEN-inactive triple-negative breast cancer. Cell Death Dis. V. 11 (2020). Art. 1001. DOI: 10.1038/s41419-020-03210-5.

Gasparyan M., Lo M-C., Jiang H., Lin C-C., Sun D. Combined p53- and PTEN-deficiency activates ex-pression of mesenchyme homeobox 1 (MEOX1) required for growth of triple-negative breast cancer. J. Biol. Chem. V. 295 (2020): pp. 12188-12202. DOI: 10.1074/jbc.RA119.010710.

Gupta S., Jones J.E., Smith-Graziani D. Disparities in Hereditary Genetic Testing in Patients with Triple Negative Breast Cancer. Clin. Breast. Cancer. V. 25 (2025): pp. 12-18. DOI: 10.1016/j.clbc.2024.09.018.

Harahap W.A., Khambri D., Panigoro S.S., Hafiz M.Z.A. Mutation of BRCA1/2 Gene in Premenopausal Triple-Negative Breast Cancer Patients in West Sumatera. Indonesian Journal of Cancer. V. 19 (2025): pp. 72-79.

Hu H., Zhu J., Zhong Y., Geng R., Ji Y., Guan Q. et al. PIK3CA mutation confers resistance to chemo-therapy in triple-negative breast cancer by inhibiting apoptosis and activating the PI3K/AKT/mTOR signaling pathway. Ann. Transl. Med. V. 9 (2021). Art. 410. DOI: 10.21037/atm-21-698.

Ing Y.H., Salleh S., Yahya M.M., Ankathil R., Aziz A. Association of ABCG2 Polymorphisms on Triple Negative Breast Cancer (TNBC) Susceptibility Risk. Asian Pac. J. Cancer Prev. V. 24 (2023): pp. 3891-3897. DOI: 10.31557/APJCP.2023.24.11.3891.

Izadi A., Naimi A., Amjadi E., Beheshtiparvar D., Soltan M. The Prevalence of PD-L1 Expression in Tri-ple-Negative Breast Cancer Patients and Its Correlation with Survival Rates and Other Prognostic Factors: A Survival Analysis. Adv. Biomed. Res. V. 13 (2024). Art. 86. DOI: 10.4103/abr.abr_2_24.

Jeong Y., Yoon S.Y., Jung S.P., Nam S.J., Lee J.E., Kim S. Inhibition of Interleukin-8/C-X-C Chemokine Receptor 2 Signaling Axis Prevents Tumor Growth and Metastasis in Triple-Negative Breast Cancer. Pharma-cology. V. 110 (2025): pp. 178-190. DOI: 10.1159/000545659.

Jiang Y-Z., Ma D., Suo C., Shi J., Xue M., Hu X. et al. Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. Cancer Cell. V. 35 (2019): pp. 428-440. DOI: 10.1016/j.ccell.2019.02.001.

Jin M., Fang J., Peng J., Wang X., Xing P., Jia K. et al. PD-1/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies. Mol. Cancer. V. 23(1) (2024). Art. 266. DOI: 10.1186/s12943-024-02176-8.

Jurj M-A., Buse M., Zimta A-A., Paradiso A., Korban S.S., Pop L-A. et al. Critical Analysis of Genome-Wide Association Studies: Triple Negative Breast Cancer Quae Exempli Causa. Int. J. Mol. Sci. V. 21 (2020). Art. 5835. DOI: 10.3390/ijms21165835.

Kim A., Jang M.H., Lee S.J., Bae Y.K. Mutations of the Epidermal Growth Factor Receptor Gene in Tri-ple-Negative Breast Cancer. J. Breast. Cancer. V. 20 (2017): pp. 150-159. DOI: 10.4048/jbc.2017.20.2.150.

Kim S., You D., Jeong Y., Yoon S.Y., Kim S.A., Lee J.A. Inhibition of platelet-derived growth factor C and their receptors additionally increases doxorubicin effects in triple-negative breast cancer cells. Eur. J. Pharmacol. V. 895 (2021). Art. 173868. DOI: 10.1016/j.ejphar.2021.173868.

Kolyadina I.V., Zavarykina T.M., Lomskova P.K., Gordeeva O.O., Kapralova M.A., Ganshina I.P. et al. The polymorphic markers of the XRCC1, ERCC5, TP53, CDKN1A1 genes and the survival of triple negative breast cancer patients after platinum-based chemotherapy. Journal of Clinical Oncology. V. 41(16_suppl) (2022). Art. e12556. DOI: 10.1200/JCO.2023.41.16_suppl.e12556.

Li H-H., Zhu H., Liu L-S., Huang Y., Guo J., Li J., Sun X-P. et al. Tumour Necrosis Factor-α Gene Poly-morphism Is Associated with Metastasis in Patients with Triple Negative Breast Cancer. Sci. Rep. V. 5 (2015). Art. 10244. DOI: 10.1038/srep10244.

Li H., Chang Y., Jin T., Zhang M. Progress of PD-1/PD-L1 immune checkpoint inhibitors in the treatment of triple-negative breast cancer. Cancer Cell Int. V. 25 (2025): Art. 139. DOI: 10.1186/s12935-025-03769-z.

Lin X., Chen H., Xie Y., Zhou X., Wang Y., Zhou J. et al. Combination of CTLA-4 blockade with MUC1 mRNA nanovaccine induces enhanced anti-tumor CTL activity by modulating tumor microenvironment of triple negative breast cancer. Transl. Oncol. V. 15 (2022). Art. 101298. DOI: 10.1016/j.tranon.2021.101298.

Liu B., Yi Z., Guan Y., Ouyang Q., Li C., Guan X. et al. Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER‐targeted therapy in HER2 amplification‐positive and HER2 mutation‐positive amplification‐negative patients. Cancer Med. V. 14 (2022): pp. 2767-2778. DOI: 10.1002/cam4.4652.

Liu J., Wang P., Huang B., Cheng Q., Duan Y., Chen L. et al. Effective suppression of triple negative breast cancer by paclitaxel nanoparticles conjugated with transmembrane TNF-α monoclonal antibody. Int. J. Pharm. V. 624 (2021). Art. 121969.

Liu L-C., Chien Y-C., Wu G-W., Hua C-H., Tsai I-C., Hung C-C. et al. Analysis of EZH2 Genetic Variants on Triple-Negative Breast Cancer Susceptibility and Pathology. Int. J. Med. Sci. V. 19 (2022): pp. 1023-1028. DOI: 10.7150/ijms.71931.

Liu Z., Li M., Jiang Z., Wang X. A Comprehensive Immunologic Portrait of Triple-Negative Breast Can-cer. Transl. Oncol. V. 11 (2018): pp. 311-329. DOI: 10.1016/j.tranon.2018.01.011.

Makrantonakis A-E., Zografos E., Gazouli M., Dimitrakakis K., Toutouzas K.G., Zografos C. et al. PD-L1 Gene Polymorphisms rs822336 G>C and rs822337 T>A: Promising Prognostic Markers in Triple Negative Breast Cancer Patients. Medicina (Kaunas). V. 58 (2022). Art. 1399. DOI: 10.3390/medicina58101399.

Mallick S., Duttaroy A.K., Dutta S. The PIK3CA gene and its pivotal role in tumor tropism of triple-negative breast cancer. Transl. Oncol. V. 50 (2024). Art. 102140. DOI: 10.1016/j.tranon.2024.102140.

Mariano N.C., Marotti J.D., Chen Y., Karakyriakou B., Salgado R., Christensen B.C. et al.. Quantitative proteomics analysis of triple-negative breast cancers. NPJ Precis. Oncol. V. 9 (2025). Art. 117. DOI: 10.1038/s41698-025-00907-8.

Mustachio L.M., Chelariu-Raicu A., Szekvolgyi L., Roszik J. Targeting KRAS in Cancer: Promising Ther-apeutic Strategies. Cancers (Basel). V. 13 (2021). Art. 1204. DOI: 10.3390/cancers13061204.

Nakai K., Hung M-C., Yamaguchi H. A perspective on anti-EGFR therapies targeting triple-negative breast cancer. Am. J. Cancer Res. V. 6 (2016): pp. 1609-1623.

Narasimhan H., Ferraro F., Bleilevens A., Weiskirchen R., Stickeler E., Maurer J. Tumor Necrosis Factor-α (TNFα) Stimulate Triple-Negative Breast Cancer Stem Cells to Promote Intratumoral Invasion and Neovasculo-genesis in the Liver of a Xenograft Model. Biology (Basel). V. 11 (2022). Art. 1481. DOI: 10.3390/biology11101481.

Navarrete-Bernal M., Cervantes-Badillo M., Martínez-Herrera J.M., Lara-Torres C.O., Gerson-Cwilich R., Zentella-Dehesa A. et al.. Biological Landscape of Triple Negative Breast Cancers Expressing CTLA-4. Front Oncol. V. 10 (2020). Art. 1206. DOI: 10.3389/fonc.2020.01206.

Obidiro O., Battogtokh G., Akala E.O. Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook. Pharmaceutics. V. 15 (2023). Art. 1796. DOI: 10.3390/pharmaceutics15071796.

Peng Z., Su P., Yang Y., Yao X., Zhang Y., Jin F. et al. Identification of CTLA-4 associated with tumor microenvironment and competing interactions in triple negative breast cancer by co-expression network analy-sis. J. Cancer. V. 11 (2020): pp. 6365-6375. DOI: 10.7150/jca.46301.

Prvanović M., Nedeljković M., Tanić N., Tomić T., Terzić T., Milovanović Z. et al.. Role of PTEN, PI3K, and mTOR in Triple-Negative Breast Cancer. Life (Basel). V. 11 (2021). Art. 1247. DOI: 10.3390/life11111247.

Qiao Y., He H., Jonsson P., Sinha I., Zhao C., Dahlman-Wright K. AP-1 Is a Key Regulator of Proin-flammatory Cytokine TNFα-mediated Triple-negative Breast Cancer Progression. J. Biol. Chem. V. 291 (2016): pp. 5068-5079. DOI: 10.1074/jbc.M115.702571.

Qodir N., Pramudhito D., Legiran, Hafy Z., Iman M.B., Syafira F. et al. Tumor Necrosis Factor-Alpha and Its Association With Breast Cancer: A Systematic Review. World J. Oncol. V. 16 (2025): pp. 143-151. DOI: 10.14740/wjon2532.

Rajaram S., Synnott N.C., Crown J., Madden S.F., Duffy M.J. Targeting mutant p53 with arsenic triox-ide: A preclinical study focusing on triple negative breast cancer. Transl. Oncol. V. 46 (2024). Art. 102025. DOI: 10.1016/j.tranon.2024.102025.

Rao Z-Z., Tang Z-W., Wen J. Advances in drug resistance of triple negative breast cancer caused by pregnane X receptor. World J. Clin. Oncol. V. 14 (2023): pp. 335-342. DOI: 10.5306/wjco.v14.i9.335.

Seehawer M., Li Z., Nishida J., Foidart P., Reiter A.H., Rojas-Jimenez E. et al. Loss of Kmt2c or Kmt2d drives brain metastasis via KDM6A-dependent upregulation of MMP3. Nat. Cell Biol. V. 26 (2024): pp. 1165-1175. DOI: 10.1038/s41556-024-01446-3.

Sghaier I., Sheridan J.M., Daldoul A., El-Ghali R.M., Al-Awadi A.M., Habel A.F. et al. Association of IL-1β gene polymorphisms rs1143627, rs1799916, and rs16944 with altered risk of triple-negative breast cancer. Cytokine. V. 180 (2024). Art. 156659. DOI: 10.1016/j.cyto.2024.156659.

Shen J., Liao Y., Hopper J.L., Goldberg M., Santella R.M., Terry M.B. Dependence of cancer risk from environmental exposures on underlying genetic susceptibility: an illustration with polycyclic aromatic hydrocar-bons and breast cancer. Br. J. Cancer. V. 116 (2017): pp. 1229-1233. DOI: 10.1038/bjc.2017.81.

Song X., Liu Z., Yu Z. EGFR Promotes the Development of Triple Negative Breast Cancer Through JAK/STAT3 Signaling. Cancer Manag. Res. V. 12 (2020): pp. 703-717. DOI: 10.2147/CMAR.S225376.

Teufelsbauer M., Stickler S., Eggerstorfer M-T., Hammond D.C., Hamilton G. BET-directed PROTACs in triple negative breast cancer cell lines MDA-MB-231 and MDA-MB-436. Breast Cancer Res Treat. V. 208 (2024): pp. 89-101. DOI: 10.1007/s10549-024-07403-w.

Tihagam R.D., Lou S., Zhao Y., Liu K., Singh A-T., Koo B.I. et al. The TRIM37 variant rs57141087 con-tributes to triple-negative breast cancer outcomes in Black women. EMBO Rep. V. 26 (2025): pp. 245-272. DOI: 10.1038/s44319-024-00331-2.

Tokumaru Y., Oshi M., Katsuta E., Yan L., Satyananda V., Matsuhashi N. et al. KRAS signaling enriched triple negative breast cancer is associated with favorable tumor immune microenvironment and better survival. Am. J. Cancer Res. V. 10 (2020): pp. 897-907.

Toney N.J., Opdenaker L.M., Frerichs L., Modarai S.R., Ma A., Archinal H. et al. B cells enhance IL-1 be-ta driven invasiveness in triple negative breast cancer. Sci. Rep. V. 15 (2025). Art. 2211. DOI: 10.1038/s41598-025-86064-1.

Vander Heiden M.G., Cantley L.C., Thompson C.B. Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation. Science. V. 324 (2009): pp. 1029-1033. DOI: 10.1126/science.1160809.

Vasiyani H., Mane M., Rana K., Shinde A., Roy M., Singh J. et al. DNA damage induces STING mediat-ed IL-6-STAT3 survival pathway in triple-negative breast cancer cells and decreased survival of breast cancer patients. Cell Signal. V. 130 (2025). Art. 111679. DOI: 10.1016/j.cellsig.2025.111679.

Vecchi L., Mota S., Zóia M., Martins I.C., de Souza J.B., Santos T.G. et al. Interleukin-6 Signaling in Tri-ple Negative Breast Cancer Cells Elicits the Annexin A1/Formyl Peptide Receptor 1 Axis and Affects the Tumor Microenvironment. Cells. V. 11 (2022). Art. 1705. DOI: 10.3390/cells11101705.

Vlajnic T., Baur F., Soysal S.D., Weber W.P., Piscuoglio S., Muenst S. PD-L1 Expression in Triple-negative Breast Cancer—a Comparative Study of 3 Different Antibodies, Appl. Immunohistochem Mol. Morphol. V. 30 (2022): pp. 726-730. DOI: 10.1097/PAI.0000000000001062.

Vodithala S., Bhake A. Detection of KRAS Mutations in Triple-negative Breast Cancers by Polymerase Chain Reaction. Journal of Datta Meghe Institute of Medical Sciences University. V. 19 (2024): pp. 71-76. DOI: 10.4103/jdmimsu.jdmimsu_703_2. EDN: XCZXOT.

Wang D-Y., Gendoo D., Ben-David Y., Woodgett J.R., Zacksenhaus E. A subgroup of microRNAs defines PTEN-deficient, triple-negative breast cancer patients with poorest prognosis and alterations in RB1, MYC, and Wnt signaling. Breast Cancer Res. V. 21 (2019). Art. 18. DOI: 10.1186/s13058-019-1098-z.

Wang L., Lu Q., Jiang K., Hong R., Wang S., Xu F. BRAF V600E Mutation in Triple-Negative Breast Cancer: A Case Report and Literature Review. Oncol Res Treat. V. 45 (2022): pp. 54-61. DOI: 10.1159/000520453.

Wang X., Venet D., Lifrange F., Larsimont D., Rediti M., Stenbeck L. et al. Spatial transcriptomics reveals substantial heterogeneity in triple-negative breast cancer with potential clinical implications. Nat. Commun. V. 15 (2024). Art. 10232. DOI: 10.1038/s41467-024-54145-w.

Wang Y-C., Wang Z-H., Yen J.H., Shen Y-C., Shen T-C., Chang W-S. et al. The Contribution of Interleu-kin-8 Rs4073 Genotypes to Triple Negative Breast Cancer Ris.k in Taiwan. Anticancer Research. V. 42 (2022): pp. 3799-3806. DOI: https://doi.org/10.21873/anticanres.15870

Wilson B.E., Shen Q., Cescon D.W., Reedijk M. Exploring immune interactions in triple negative breast cancer: IL-1β inhibition and its therapeutic potential. Front Genet. V. 14 (2023). Art. 1086163. DOI: 10.3389/fgene.2023.1086163.

Xiang S., Zhaoyun L., Zhiyong Y. EGFR Promotes the Development of Triple Negative Breast Cancer Through JAK/STAT3 Signaling. Cancer Manag. Res. Jan 30; 12 (2020): pp. 703-717. DOI: 10.2147/CMAR.S225376. eCollection 2020.

Yadav B.S., Chanana P., Jhamb S. Biomarkers in triple negative breast cancer: A review. World J. Clin. Oncol. V. 6 (2015): pp. 252-263. DOI: 10.5306/wjco.v6.i6.252.

Yi H., Li Y., Tan Y., Fu S., Tang F., Deng X. Immune Checkpoint Inhibition for Triple-Negative Breast Cancer: Current Landscape and Future Perspectives. Front Oncol. V. 11 (2021). Art. 648139. DOI: 10.3389/fonc.2021.648139.

Zafari Y., Homaei A., Bahadoran E. High Concentration of TNF-α Can Involved in Malignancy Promo-tion of Triple-Negative Breast Cancer Patients. Journal of Inflammatory Diseases. V. 28 (2024). Art. e159095.

Zagami P., Carey L.A. Triple negative breast cancer: Pitfalls and progress. NPJ Breast Cancer. V. 8 (2022). Art. 95. DOI: 10.1038/s41523-022-00468-0.

Zhang Z., Zhang R., Li D. Molecular Biology Mechanisms and Emerging Therapeutics of Triple-Negative Breast Cancer. Biologics. V. 17 (2023): pp. 113-128. DOI: 10.2147/BTT.S426392.

Zhou J., Ottewell P.O. The role of IL-1B in breast cancer bone metastasis. J. Bone. Oncol. V. 46 (2024). Art. 100608. DOI: 10.1016/j.jbo.2024.100608.

Наиболее читаемые статьи этого автора (авторов)